[Johnson & Johnson] Johnson & Johnson announced Phase I results for JNJ-6143, an investigational once-daily oral Regulated Induced Proximity Targeting Chimera small molecule, in patients with advanced prostate cancer who had received multiple prior treatments. Among patients with measurable disease, 75% had a confirmed complete or partial response.

[Syncromune, Inc.] Syncromune, Inc. announced updated overall survival results from a Phase I trial of its investigational SYNC-T Therapy SV-102 in patients with metastatic prostate cancer.

[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA has expanded approval of TALZENNA^® (talazoparib) in combination with XTANDI^® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations.

[European Journal of Pharmacology] Scientists proposed that hyperoside (HYP) exerts its anti-prostate cancer activity by inducing ferroptosis via flotillin-2 (FLOT2) downregulation. Mechanistically, HYP interacts with FLOT2, suppresses STAT3-mediated indoleamine 2,3-dioxygenase 1 expression, thereby blocking tryptophan metabolism and interrupting kynurenine-aryl hydrocarbon receptor signaling.

[Advanced Materials] Paired proteomic profiling of specimens from ten patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 metastatic hormone-sensitive prostate cancer patients.

[Advanced Science] Paired proteomic profiling of specimens from ten patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 metastatic hormone sensitive patients.

[Acta Biomaterialia] Researchers exploited a genetic approach to display both anti-human prostate-specific membrane antigen and anti-human CD3 antibodies on exosomal surface. Through simultaneously targeting T cells and prostate cancer tumors, the resulting prostate cancer immunotherapeutic exosomes were designed to induce robust anti-cancer cellular immunity.

[BJU International] The authors conducted a systemic review and meta-analysis to assess the associations between intracellular acid phosphatase 1 (ACP1) and ACP3 expression and clinical outcomes, including disease presence, Gleason grade, tumor stage, lymph node involvement, and patient survival in prostate cancer.

[International Journal of Pharmaceutics] Investigators encapsulated abazitaxel in polycaprolactone polymeric nanoparticles functionalized with transferrin, and evaluated its in vitro activity in prostate cancer cell lines.

[Nature Medicine] The authors generated a single-nucleus RNA sequencing atlas from 189 primary colorectal cancer tumors spanning eight decades of life, with at least 20 tumors in most age decades.

[Gut] Researchers aimed to investigate whether intrinsic tumor features are associated with an enhanced propensity for liver metastasis in gastric cancer and to identify the key transcriptional regulators and downstream mechanisms contributing to this organ-specific dissemination.

[Nature Communications] Using colonic biopsies from patients with ulcerative colitis and mouse models enabling tissue-wide visualization of the transcription factor NF-κB activity, scientists combined single-cell RNA sequencing and secretome analysis to define epithelial communication during colitis.